Selinco receives EU approval

H. Lundbeck A/S (OMX: LUN) and its partner Biotie Therapies (OMXH: BTH1V) said that Selincro (nalmefene) has been approved as a treatment for the reduction of alcohol consumption in high drinking risk individuals. Predicting sales is an arduous tasks given the pioneering nature of the drug with the new treatment paradigm and the need to administer the drug in combination with continuous psychosocial support. The drug is expected to launch mid-year.